Sonnet BioTherapeutics Holdings Investor Relations Material

Sonnet BioTherapeutics Holdings Inc is a U.S.-based clinical-stage biopharmaceutical company focused on the development of innovative biologic drugs for cancer and other serious diseases. The company utilizes a proprietary platform to design fully human fusion proteins that enhance the therapeutic activity and delivery of cytokines. Sonnet’s pipeline targets various solid tumors and immunological conditions, with development efforts supported by preclinical and clinical research. The company is headquartered in Princeton, New Jersey, and its shares are listed on the NASDAQ.